A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY)

Retreatment with twelve weeks of SOF/VEL/VOX was safe and effective in patients with relapsed HCV following initial combination DAA-based treatment. Treatment response was not diminished with HIV-infection or previous noncompletion of or poor adherence to DAA-based therapy.

Source: Journal of Hepatology - June 3, 2019 Category: Gastroenterology Authors: Eleanor Wilson, Emily Covert, Jennifer Hoffmann, Emily Comstock, Benjamin Emmanuel, Lydia Tang, Jennifer Husson, Joel Chua, Angie Price, Poonam Mathur, Elana Rosenthal, Sarah Kattakuzhy, Henry Masur, Shyam Kottilil Source Type: research